ALT Relative Valuation
ALT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALT is overvalued; if below, it's undervalued.
Historical Valuation
Altimmune Inc (ALT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.72. The fair price of Altimmune Inc (ALT) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：5.31
Fair
-4.68
PE
1Y
3Y
5Y
Trailing
Forward
-2.96
EV/EBITDA
Altimmune Inc. (ALT) has a current EV/EBITDA of -2.96. The 5-year average EV/EBITDA is -2.72. The thresholds are as follows: Strongly Undervalued below -6.44, Undervalued between -6.44 and -4.58, Fairly Valued between -0.85 and -4.58, Overvalued between -0.85 and 1.01, and Strongly Overvalued above 1.01. The current Forward EV/EBITDA of -2.96 falls within the Historic Trend Line -Fairly Valued range.
-2.79
EV/EBIT
Altimmune Inc. (ALT) has a current EV/EBIT of -2.79. The 5-year average EV/EBIT is -3.02. The thresholds are as follows: Strongly Undervalued below -7.36, Undervalued between -7.36 and -5.19, Fairly Valued between -0.85 and -5.19, Overvalued between -0.85 and 1.33, and Strongly Overvalued above 1.33. The current Forward EV/EBIT of -2.79 falls within the Historic Trend Line -Fairly Valued range.
148108.22
PS
Altimmune Inc. (ALT) has a current PS of 148108.22. The 5-year average PS is 26495.43. The thresholds are as follows: Strongly Undervalued below -76741.57, Undervalued between -76741.57 and -25123.07, Fairly Valued between 78113.92 and -25123.07, Overvalued between 78113.92 and 129732.42, and Strongly Overvalued above 129732.42. The current Forward PS of 148108.22 falls within the Strongly Overvalued range.
-6.89
P/OCF
Altimmune Inc. (ALT) has a current P/OCF of -6.89. The 5-year average P/OCF is -1.63. The thresholds are as follows: Strongly Undervalued below -42.00, Undervalued between -42.00 and -21.81, Fairly Valued between 18.56 and -21.81, Overvalued between 18.56 and 38.75, and Strongly Overvalued above 38.75. The current Forward P/OCF of -6.89 falls within the Historic Trend Line -Fairly Valued range.
-5.46
P/FCF
Altimmune Inc. (ALT) has a current P/FCF of -5.46. The 5-year average P/FCF is -5.49. The thresholds are as follows: Strongly Undervalued below -10.46, Undervalued between -10.46 and -7.98, Fairly Valued between -3.01 and -7.98, Overvalued between -3.01 and -0.52, and Strongly Overvalued above -0.52. The current Forward P/FCF of -5.46 falls within the Historic Trend Line -Fairly Valued range.
Altimmune Inc (ALT) has a current Price-to-Book (P/B) ratio of 2.74. Compared to its 3-year average P/B ratio of 2.62 , the current P/B ratio is approximately 4.43% higher. Relative to its 5-year average P/B ratio of 2.45, the current P/B ratio is about 11.43% higher. Altimmune Inc (ALT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -22.70%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -20.51% , the current FCF yield is about -100.00% lower.
2.74
P/B
Median3y
2.62
Median5y
2.45
-12.45
FCF Yield
Median3y
-22.70
Median5y
-20.51
Competitors Valuation Multiple
The average P/S ratio for ALT's competitors is 0.00, providing a benchmark for relative valuation. Altimmune Inc Corp (ALT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 0.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ALT decreased by 26.35% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 5.00K to 5.00K.
The secondary factor is the P/E Change, contributed -9.58%to the performance.
Overall, the performance of ALT in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Altimmune Inc (ALT) currently overvalued or undervalued?
What is Altimmune Inc (ALT) fair value?
How does ALT's valuation metrics compare to the industry average?
What is the current P/B ratio for Altimmune Inc (ALT) as of Dec 05 2025?
What is the current FCF Yield for Altimmune Inc (ALT) as of Dec 05 2025?
What is the current Forward P/E ratio for Altimmune Inc (ALT) as of Dec 05 2025?